Mirae Asset China, a part of South Korea’s Mirae Asset Financial Group, has led a $50 million Series C funding round for Puliyan, a rapidly growing medical aesthetics startup from Nanjing, China. Previous investors Alwin Capital and Huatai Zijin Investment also joined the round.
Puliyan was founded in May 2018 and focuses on regenerative aesthetics.
This is a new type of skincare that works by boosting the body’s natural healing process to improve skin health over time, instead of just offering temporary cosmetic fixes.
Puliyan has received two top-level (Class III) medical device approvals from China’s National Medical Products Administration (NMPA).
These approvals cover treatments like Sculptra, an injection that boosts collagen, and thread lifting, a gentle procedure to lift the skin—both aimed at improving deep skin health.
Puliyan has more than 4,000 square meters of fully automated production space. The company plans to use the new funding to launch more regenerative skincare products, many made from natural or recycled materials, and to expand their use in medical treatments across China and other countries.
Jim Wang (Wang Jinyin), Co-CEO of Mirae Asset China, said the firm will support Puliyan in improving its products and expanding into clinical use.
He added that they will also help Puliyan grow internationally, as part of a larger move in China’s beauty industry toward regenerative treatments.
Mirae Asset, founded in 1997 and based in Seoul, is one of Asia’s top financial companies. It manages over $620 billion in assets worldwide, including more than $15.8 billion in equity investments as of June 2025.
Read more- Inflection Point Ventures Launches $110M Global Startup Fund
